



Tavola Rotonda: «Il Trapianto renale»

9 maggio 2023

Moderatori: Cristiana Dente, Piera Rossetto Casel


Quando il trapianto perde la sua efficacia, il percorso di rientro in dialisi

Gabriele Donati

SC Nefrologia Dialisi e Trapianto renale



UNIMORE
UNIVERSITÀ DEGLI STUDI DI
MODENA E REGGIO EMILIA



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**
Azienda Ospedaliero-Universitaria di Modena

No Consensus on the Definition of a Failing Kidney Allograft

- **Stable but low allograft function (GFR < 20 ml/min)**
- **Declining function**
- **Return to renal replacement therapy**

Outcomes after a First-time Kidney Transplantation

CHAPTER 7: TRANSPLANTATION



vol 2 Table 7.3 Trends in 1-, 5-, & 10-year deceased donor kidney transplant outcomes, 1997-2013

Year	One year post-transplant			Five years post-transplant			Ten years post-transplant		
	Prob. of all-cause graft failure	Prob. of return to dialysis or repeat transplant	Prob. of death	Prob. of all-cause graft failure	Prob. of return to dialysis or repeat transplant	Prob. of death	Prob. of all-cause graft failure	Prob. of return to dialysis or repeat transplant	Prob. of death
1997	13.9%	8.1%	6.1%	34.2%	23.4%	19.2%	57.9%	41.0%	39.3%
1998	13.5%	8.3%	5.5%	33.2%	23.5%	18.2%	56.4%	40.3%	38.0%
1999	14.3%	8.4%	5.9%	33.4%	22.7%	18.8%	56.3%	39.2%	38.2%
2000	13.7%	7.9%	6.4%	34.0%	22.7%	19.7%	56.7%	38.6%	39.2%
2001	12.7%	7.6%	5.7%	32.9%	21.1%	19.8%	55.2%	36.7%	38.6%
2002	12.7%	7.8%	5.6%	32.5%	21.8%	18.8%	53.5%	35.8%	37.1%
2003	12.4%	7.3%	5.6%	31.7%	20.3%	18.4%	54.4%	35.8%	37.6%
2004	11.8%	7.1%	5.4%	31.2%	20.5%	18.3%	53.1%	35.4%	36.7%
2005	11.5%	6.9%	6.0%	29.9%	19.1%	17.8%			
2006	10.8%	6.6%	5.1%	29.3%	18.7%	17.1%			
2007	9.8%	5.9%	4.6%	28.2%	17.7%	16.9%			
2008	9.6%	6.0%	4.5%	26.8%	16.1%	16.3%			
2009	9.4%	5.6%	4.9%	26.8%	16.3%	16.1%			
2010	8.8%	5.4%	4.4%						
2011	7.3%	4.3%	3.9%						
2012	7.8%	4.8%	3.8%						
2013	7.7%	4.8%	3.5%						

Transitions between Transplantation and Dialysis

	Years: 1995-2003		
	Wait-listing	Functioning graft	Dialysis return
▪ Patients (n)	89202	43433	5461
▪ Age (yrs,SD)	49.6(13.0)	49.2(13.2)	47.9(13.5)
▪ Male (%)	60.1	61.7	60.7
▪ Dialysis before waiting list (mths)			
< 12	56.5	63.3	65.9
12-23	26.7	24.3	23.5
≥ 24	16.8	12.4	10.6
▪ Deaths, n(%)	10836(12.2)	4927(10.4)	1474(27.0)
Sepsis, n(%)	1562(14.4)	539(10.9)	230(15.6)
CHF, n (%)	4891(45.1)	788(16.0)	553(37.5)

$$\text{Death per 100 patient years} = \frac{\text{Deaths (n)}}{\text{Sum of observation period of each patient}}$$





Back to Dialysis after Graft Failure vs. Incident Dialysis Patients

Survival: Full cohort



Propensity Score Adjusted



	Incident HD N = 4898	Graft failure N=318	P-value
Age, years	69±14	61±14	<0.001
Charson score	3.1±1.3	2.8±1.1	<0.001
Female (%)	35	65	<0.001
Fistula (%)	46	66	<0.001
HDF (%)	62	44	<0.001
Qb, ml/min	380±56	400±55	<0.001
Hb, gr/dL	10.3±1.5	10.3±1.5	ns

	Incident HD N = 480	Graft failure N=240	P-value
Age, years	61±18	61±13	ns
Charson score	2.7±1.1	2.8±1.0	ns
Female (%)	64	63	ns
Fistula (%)	61	64	ns
HDF (%)	46	45	ns
Qb, ml/min	400±51	400±52	ns
Hb, gr/dL	10.2±1.6	10.3±1.5	ns



Mortality after Renal Allograft Failure and Return to Dialysis

Amarpali Brar^a Mariana Markell^a Dimitre G. Stefanov^b
Edem Timpo^a Rahul M. Jindal^d Robert Nee^{e,f} Nabil Sumrani^c
Devon John^c Fasika Tedla^a Moro O. Salifu^a


Variables	Adjusted Hazard Ratio	95% Confidence Interval	P-value
Age, years	1.033	1.027-1.038	<0.0001
AVF vs CVC	0.778	0.643-0.943	0.01
Graft vs CVC	0.58	0.398-0.847	0.005
Overweight vs normal BMI	0.854	0.749-0.973	0.02
Underweight vs normal BMI	1.305	1.076-1.583	0.006
Albumin < 3.5gr%	1.329	1.180-1.496	<0.0001
Peripheral arterial disease	1.404	1.211-1.628	<0.0001
Cerebrovascular disease	1.431	1.211-1.691	<0.0001

Managing Patients with Failing Kidney Allograft

Many Questions Remain

Scott Davis ^{1,2,3} and Sumit Mohan ^{1,2,3}

CJASN 17: 444-451, 2022. doi: <https://doi.org/10.2215/CJN.14620920>



Immunosoppressione

1. Transizione al Belatacept per ridurre la perdita di GFR
2. Ottimizzare il bilancio tra i rischi di infezione e di rigetto
3. Décalage in base alla possibilità di un secondo trapianto
4. Evitare la nefrectomia


Ritrapianto

1. Identificare un donatore vivente
2. Inserimento in lista «preemptive» appena GFR < 20 ml/minuto
3. Ottimizzare l'immunosoppressione se disponibile un donatore
Ritrapianto tempestivo in base al GFR
4. Reclutamento del donatore vivente

Raccomandazioni per la **Transizione**

1. Gestione dell'anemia e dell'iperparatiroidismo
2. Accesso vascolare o catetere peritoneale tempestivo
3. Identificare la necessità di cure palliative
4. Identificare la necessità di early referral
5. Consigliare la tipologia di dialisi compresa la dialisi domiciliare

The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients



Repeat Transplant Candidate

- Avoid sensitization
- Facilitate pre-emptive transplant
- Avoid transplant nephrectomy


Residual Renal function

- Avoid rejection
- Avoid graft intolerance
- Improve transition to dialysis

Complications of Immunosuppression

- Infections
- Malignancy
- Atherosclerotic disease

La Gestione della Terapia Immunosoppressiva dopo Fallimento del Trapianto




Effect of reduced immunosuppression on risk of cancer: population retrospective cohort study

- ❖ 1 January 1982 – 30 September 2003, patients(n) = 7,809
- ❖ Failure of the first renal transplant, (%) = 23
- ❖ Second renal transplant, (%) = 9
- ❖ Three or more renal transplant, (%) = 1




ANZ DATA AUSTRALIA & NEW ZEALAND DIALYSIS & TRANSPLANT REGISTRY



Fever, Infection, and Rejection After Kidney Transplant Failure

Kenneth J. Woodside,¹ Zachary W. Schirm,¹ Kelly A. Noon,¹ Anne M. Huml,² Aparna Padiyar,² Kund Q. Sanchez,¹ Nagaraju Sarabu,² Donald E. Hricik,² James A. Schulak,¹ and Joshua J. Augustine^{2,3}

IMMUNOSUPPRESSION	WEANED n = 143	FULL N = 43	P- value
Age, years	46 ± 14	43 ± 11	Ns
Females, (%)	46	40	ns
Duration TX, months	72 (1-306)	92 (1-276)	ns
Living donor, (%)	27	14	ns
Hospitalization with fever (%)	45	40	ns
Hospitalization with infection (%)	17	35	0.01
Allograft nephrectomy (%)	42	26	0.05




Prevention of Sepsis during the Transition to Dialysis May Improve the Survival of Transplant Failure Patients

Olwyn Johnston, Nadia Zalunardo, Caren Rose, and John S. Gill

Division of Nephrology, University of British Columbia, St. Paul's Hospital; Vancouver, British Columbia, Canada

Variables	Hazard Ratio	95% CI	P-value
Septicaemia	2.93	2.64-3.24	<0.001
Multiple sepsis episodes	1.47	1.26-1.73	<0.001
Age at transplant failure ≥ 60	2.20	1.98-2.46	<0.001
BMI ≥ 30	0.84	0.74-0.96	0.01
Diabetes	1.89	1.70-2.09	<0.001
Cadaveric donor	1.23	1.10-1.39	<0.0001
Ischemic heart disease	1.57	1.33-1.85	<0.0001




JASN[®]

Initial Vascular Access Type in Patients with a Failed Renal Transplant

Micah R. Chan,* Bharvi Oza-Gajera,* Kevin Chapla,* Arjang X. Djamali,*[†] Brenda L. Muth,* Jennifer Turk,*
Maureen Wakeen,* Alexander S. Yevzlin,* and Brad C. Astor*[‡]


- ❖ 1 January 2006 – 30 September 2011
 - ❖ Patients (n) = 16,728 Kidney allograft failure
 - ❖ Patients (n) = 509, 643 Native kidney failure
- } **Dialysis Start**

Variables	Hazard Ratio	95% CI	P-value
Age (per 10 yrs)	0.85	0.84-0.87	<0.001
Women	1.75	1.63-1.87	<0.001
Afro-American	0.77	0.72-0.83	<0.001
PVD	1.31	1.16-1.48	<0.001
Diabetes	1.14	1.06-1.22	0.001
Institutionalized	1.53	1.23-1.89	<0.0001
None Nephrology Referral	2.00	1.72-2.33	<0.0001




Kidney Transplant after a Failed Allograft

Trapianti eseguiti



Inserimenti in Lista d'Attesa



Indicazioni alla Transplantectomia dopo Trapianto di Rene

Prima di 12 mesi dal Trapianto

1. Perdita precoce del trapianto
2. Trombosi vascolare
3. Rigetto acuto
4. Rigetto iperacuto
5. Infezione urinaria ricorrente o sepsi

Dopo 12 mesi dal Trapianto

1. Infiammazione cronica
2. Nefropatia da Polyomavirus
3. Cancro
4. Sindrome da intolleranza del Graft
5. Infezione urinaria ricorrente o sepsi

Sindrome da Intolleranza del Graft

Sintomi e segni comuni

- Febbre
- Macroematuria
- Edema perirenale
- Nefromegalia
- Tensione del Graft

Sintomi e Segni meno comuni

- Malessere generale
- Calo ponderale
- Trombocitopenia
- Resistenza all'EPO
- Aumento PCR e VES


Transplant Nephrectomy Improves Survival following a Failed Renal Allograft

Juan Carlos Ayus,* Steven G. Achinger,† Shuko Lee,‡ Mohamed Alan S. Go^{¶¶}

❖ 1 January 1994 – 31 December 2004

❖ Total USRDS patients (n) = 10,951


❖ Allograft nephrectomy,(n) = 3,451 (31.5%)



Analysis	Adjusted Hazard Ratio for Death for Nephrectomy vs. NON Nephrectomy	95% Confidence Interval
Original cohort (n = 10,951)	0.69	0.63-0.74
Original cohort with adjustment for transplant center (n = 10,951)	0.69	0.63-0.74
Original cohort + patients whose transplants failed < 90 days after initial transplant date (n = 13,702)	0.67	0.63-0.71
Subset of original cohort who survived ≥ 30 days after transplant failure (n = 10,886)	0.69	0.66-0.74
Original cohort + patients without documented Medicare fee-for-service coverage within 90 days after transplant failure (n = 14,352)	0.67	0.63-0.72
Original cohort + patients with two transplant in which the transplant sequence was uncertain or unknown (n = 11,237)	0.68	0.63-0.73
Subset of original cohort whose duration of transplant before failure was < 12 months (n=1545)	0.76	0.65-0.90
Subset of original cohort whose duration of transplant before=failure was ≥ 12 months (n=9,318)	0.65	0.60-0.71

Nephrectomy After Transplant Failure: Current Practice and Outcomes

O. Johnston^a, C. Rose^a, D. Landsberg^a,
W. A. Gourlay^b and J. S. Gill^{a,c,*}





SHORT TERM COMPLICATIONS	Graft survival < 1 year N = 2,094	Graft survival < 1 year N = 4,119	P-value
• Events during hospital admission			
Myocardial infarct	0.9%	0.5%	NS
Congestive heart failure	4.0%	2.7%	<0.01
Sepsis	6.1%	2.9%	<0.0001
Death	1.0%	1.1%	NS
• Events within 90 days of hospital admission			
Myocardial infarct	1.5%	1.1%	NS
Congestive heart failure	7.1%	7.5%	NS
Sepsis	10.7%	6.2%	<0.0001
Death	5.0%	4.7%	NS

	Patients with EARLY graft failure		Patients with LATE graft failure	
	DEATH	SEPSIS	DEATH	SEPSIS
Hazard ratio	1.13	1.09	0.89	0.88
95% CI	1.01-1.26	0.95-1.24	0.83-0.95	0.81-0.96

Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy

Arnaud Del Bello,* Nicolas Congy-Jolivet,^{†‡} Federico Sallusto,[§] Celine Guilbeau-Frugier,^{||} Isabelle Cardeau-Desangles,* Marylise Fort,[‡] Laure Esposito,* Joelle Guitard,* Olivier Cointault,* Laurence Lavayssière,* Marie Béatrice Nogier,* Antoine Blancher,^{†‡} Lionel Rostaing,^{*†} and Nassim Kamar^{*†}


*D



❖ February 2007 – July 2008, patients (n) = 31
Clinically indicated

❖ July 2008- November 2010, patients (n) = 17
Systematic transplantectomy

Death or Retransplant after a Failed Allograft




Intensive Home Hemodialysis Survival Comparable to Deceased Donor Kidney Transplantation

Angie G. Nishio-Lucar^{1,3}, Subhasish Bose^{1,2,3}, Genevieve Lyons¹, Kwabena T. Jennie Z. Ma¹ and Robert S. Lockridge Jr^{1,2}

Check for updates

Intensive Home Hemodialysis
Hemodialysis treatment 4 or more times per week, preferably totalling 20 hours or more and eliminating the 2 day interdialytic gap.

- IHHD = 116 patients
- Living donor KT = 1212 patients
- Deceased donor KT = 1834 patients





	DD KT vs IHHD		LD KT vs IHHD	
Modal Type	Hazard ratio (95%CI)	P -value	Hazard ratio (95%CI)	P -value
Unadjusted	0.92 (0.80-1.41)	ns	0.53 (0.34-0.83)	0.005
Adjusted	0.96 (0.62-1.48)	ns	0.69 (0.44-1.08)	ns
PS-adjusted	0.96 (0.62-1.49)	ns	0.60 (0.37-0.96)	ns
PS-adjusted	1.06 (0.46-2.49)	ns	0.80 (0.47-1.35)	ns

Outcome della Dialisi Peritoneale dopo il Fallimento del Trapianto



	PD post Tx group N= 328	Control PD group N= 656
Age, years	50(19.5-82.6)	50.8(18.2-91.4)
Male, n (%)	166(50.6)	341(52)
Charlson score	4 (3-11)	4 (3-14)
Diabetes, n(%)	45 (13.7)	162 (24.7)

Fattori Predittivi	Odds Ratio	95% CI	P-Value
Età, per anno	0.99	0.98-0.99	0.03
Uomini	0.75	0.60-0.93	0.01
Fallimento TX	1.62	1.30-2.01	<0.0001
Peritoniti	1.38	1.12-1.71	0.002



Dialisi Peritoneale vs Emodialisi dopo Fallimento del Trapianto

	PD post TX N= 21	HD post TX N= 39
Age, years	46 (36-57)	49(34-60)
Males, (%)	43	62
Duration TX, months	144 (27-176)	59 (9-131)
CRP, mg/L	14 (10-39))	20 (6-38)



Reduced survival and quality of life following return to dialysis after transplant failure: the Dialysis Outcomes and Practice Patterns Study



- ❖ DOPPS 1-2-3 (1996-2008)
- ❖ Patients (n) = 1,856 Kidney allograft failure
- ❖ Patients (n) = 2, 806 Native kidney failure
- ❖ SF-36: eight scales, score 0-100
- ❖ KDQOL-SF: three scales, score 0-100
- ❖ PCS: Physical component summary
- ❖ MCS: Mental component summary

		TN patients N = 2806	TF patients N= 1856	P- value	TF patients			P- value
					< 3 months (n=313)	3-12 months (n=299)	12 months (n=1244)	
PCS	Physical component summary	39.6	37.1	<0.0001	36.4	36.5	37.4	Ns
SF-36	Physical functioning	54.2	47.3	<0.0001	46.2	47.7	47.4	Ns
SF-36	Role Physical	42.3	34.7	0.0007	25.9	30.8	37.5	0.03
SF-36	General health	46.9	42.4	0.0005	41.0	40.4	43.1	Ns
SF-36	Bodily pain	66.3	60.8	0.0001	59.1	59.4	61.4	Ns
MCS	Mental component summary	46.5	44.8	Ns	43.5	43.9	45.3	Ns
SF-36	Mental health	65.1	61.5	Ns	59.2	61.5	62	Ns
SF-36	Role emotional	59.6	55.8	Ns	49.5	54.2	57.6	Ns
SF-36	Social functioning	65.8	60.6	0.02	60.6	56.1	61.6	Ns
SF-36	Vitality	45.5	38.8	0.0002	33.7	38.5	40.0	Ns
KDQOL-SF	Burden	40.4	38.2	Ns	40.4	35.9	38.3	0.002
KDQOL-SF	Effects	61.5	57.3	Ns	60.0	55.8	57.1	0.0004
KDQOL-SF	Symptoms	75.3	72.3	0.02	71.0	70.8	72.9	Ns



Management of the Failing Kidney Transplant

Compiled by a Working Party of
The British Transplantation Society
May 2014

Psychosocial Issues

1. **Graft failure can have profound psychological effects on patients (depression, suicidal ideation) and close family members**
2. **There is often psychological resistance from both the patient and clinician to accept that a transplant is failing**
3. **When transplant failure occur patients are often ill-prepared to cope with the emotions experienced**
4. **Common emotions are grief, guilt, anger, loss of self esteem, and fear**
5. **Transplanted patients may be out of touch with current treatments and need to receive up to date information**

Take Home Messages